

27 March 2021

## China Market Strategy

### Value Striking Back

- ⊖ The strength in growth stocks relative to value stretched to an unprecedented high, before it began to unwind in late June 2020. It had gone almost unnoticed till the value rotation really started to gather momentum in late November 2020. The singular growth strength, established upon credit expansion, growth extrapolation and greed, and facilitated by the extremely low-cost internet brokers, can be best described as a “COVID Bubble” – both in the US and China. When we published our 2H20 outlook “**The Dragon Awaits**” last June, we first hinted at the emerging value rotation. In our 2021 outlook “**Value Strikes Back**”, we recommended value, commodities and Bitcoin, with EM, China and HK as the long-term opportunities.

Now, this bubble is threatened by rising bond yield and volatility, and is starting to deflate. Sticking to growth is really extrapolating linearly the growth during the pandemic. Thus, such thinking is a true lack of imagination, which is essential to long-term growth investing. And such thinking is downright pessimism, as it projects the pandemic growth pattern to continue forever.

- ⊖ A global recovery is unfolding. The economic cycles of the US and China are more intertwined than ever, as Chinese exports have become an even more important input for the paused US. Upstream inflation in China in the coming months, as evidenced in the strength of commodities, will likely be reflected in rising US bond yields and bond volatility. Growth stocks are long-duration assets, and thus are sensitive to rising yields and volatility. Simply put, rising yields depress growthy multiples, while heightened volatility makes people more anxious to cash in on the phenomenal gains in growth stocks. Continue to rotate into value.
- ⊖ Cyclical and commodities’ strength as a whole is in full swing. A vexing question is where to put money during the next phase of recovery. While cyclical and commodities are definite terms, value is not. Given the circumstances, we can use valuation as a proxy for value. Or that “value investing” now is similar to “valuation investing”. Both cyclical value and non-cyclical value are reverting their weakness, but still below long-term average. The opposite is true for cyclical growth and non-cyclical growth. There is still value to be gained in cyclical and non-cyclical value sectors, such as consumption, industrials, financials and telecoms.
- ⊖ That said, geopolitical risks are rising. Harsh rhetoric was exchanged, and new sanctions were imposed. These risks will hamper the market. China’s RRR is unlikely to move as a show of economic strength, while credit expansion is hindered by the property bubble. Historically, the RMB’s weakness is concurrent with economic and geopolitical risks, as in 2008 and 2018. The change in valuation as measured by market cap to GDP suggests limited index gains. As such, we continue to believe that the opportunity lies more in value rotation, rather than overall absolute index level. Of course, don’t confuse short-term fluctuations in bonds, stocks, and commodities with China’s secular rise.

**Hao Hong, CFA**

hao.hong@bocomgroup.com  
(852) 3766 1802

Head of Research

## Value Striking Back

### A Global Recovery

The recovery is here. Barring further COVID uncertainties, the recovery is likely to persist, and its strength to exceed expectations in the near term. By popular demand, we have been on an extensive book tour in the past few months to meet with our readers and fans, many of them with professional investment background. Our book ***Forecast: the Economy, Cycles and Market Bubbles*** has been re-printed 10 times within 4 months since its publication.

During our book tour, the Shanghai Composite had risen slightly above the upper bound of our forecast trading range of 2,900-3,600 laid out in our outlook report last November. When we published our 2H20 outlook ***The Dragon Awaits*** last June, we first hinted at the emerging value rotation. In our 2021 outlook ***Value Strikes Back***, we recommended value, commodities and Bitcoin, with EM, China and HK as the long-term opportunities. Obviously, market participants want our forecasts for the market's next move. It is the question most frequently asked during our tour, and the most challenging part of our job.

To see where China's monetary cycle is, we compare the change in China's RRR versus the spot price of rebar (**Figure 1**). These two variables are closely correlated. The change in RRR is plateauing, suggesting that the easing phase by cutting RRR is largely done. If the economy cools due to China's self-imposed restraints on monetary easing and credit expansion, then RRR will be cut again. But that is not our base case. RRR is unlikely to move for some time, similar to the cycle from 2013 to 2014, as well as from 2017 to early 2018. At this stage, any cut in RRR will be seen as weakness in the economy, and will actually invite sell-off of cyclical assets.

**Figure 1: Change in RRR vs. rebar suggests recovery, but commodity strength appears plateauing**




Source: Bloomberg, BOCOM Int'l estimates

## China Market Strategy

In the US, the recovery is also underway. We measure the forward component of the US consumer expectation versus the US treasury yield curve, as well as the performance of S&P 500 index. These important and reliable leading economic indicators are simultaneously suggesting a strong recovery (**Figure 2**). Our European indicators are pointing in the same direction (not shown here). With COVID contained as our base case, a concurrent recovery in the world's largest economies is likely to go from strength to strength. These observations are consistent with our forecasts laid out in our outlook report **"Outlook 2021: Value Strikes Back"** (2020-11-20).

**Figure 2: The US forward consumer expectation, yield curve and S&P500 are all showing recovery**




Source: Bloomberg, BOCOM Int'l estimates

## The Interlocking Economies of the US and China

The US and Chinese economies are so interconnected that many of their economic variables are highly correlated. Indeed, in our eyes, there is really only one economic cycle to analyze. Back on September 3, 2018, we published a ground-breaking research paper **"The Colliding Cycles of the US and China"** on the economic cycles of the US and China, and how these cycles are intertwined to influence the market. We used quantitative methods to prove that the short economic cycles of around 3 years ripple through both economies, and how the Chinese cycle leads the US, and how these short cycles join into interim and secular cycles.

This relationship between the China and US cycles persists, and the key economic variables continue to be highly correlated. Indeed, we would argue that because Chinese exports have been an even more important input for the US economy, given the different management of the pandemic, the cycles between the two countries must now be even more intertwined. As such, China's inflation outlook, for instance, will continue to affect the US bond yields significantly. And the US bond yields, long been a global risk-free benchmark, will in turn exert its influence on the Chinese stock market. Indeed, we can see these interconnections in their full strength from the following charts (**Figure 3**).

**Figure 3: The US and China's economic cycles highly intertwined; all key variables closely correlated**


Source: Bloomberg, BOCOM Int'l estimates

## Value Striking Back

To see where China's credit cycle is, we compare China's credit conditions with the relative performance of growth stocks versus value (**Figure 4**). We can see that credit expansion drives growth stocks' relative strength, and vice versa. We note that the strength in growth stocks started back in 2019, when China's economic cycle turned up from the nadir of the China-US trade war. But in 2020, the relative strength in growth stocks really stretched to an unprecedented height, with continuing credit expansion and the spread of COVID.

It is likely that the pandemic altered the market perception of growth stocks, many of which are internet platform companies. After all, these companies had shown earnings resilience when confronted by the rampage of COVID. The strong earnings fundamentals,

## China Market Strategy

the expanding credit conditions and the shifting expectations during the pandemic together were necessary conditions to germinate a “COVID bubble” in the growth stocks. The extremely low-cost internet brokers facilitate this process. But we would caution against extrapolating this growth during an unusual period.

Post COVID, the economy is recovering and no longer shrinking. In a growing economy, the relative strength of growth will wane. Or growth stocks are no longer taking market share from value stocks. And this is indeed the case now (**Figure 4**). Growth stocks will no doubt continue to grow – don’t get us wrong, but the unreasonable growth expectations embedded in their valuation will likely subside – as they are now. And the COVID bubble is now deflating.

**Figure 4: Credit expansion drives the relative strength of growth vs. value**



Source: Bloomberg, BOCOM Int'l estimates

For the US, our quantitative analysis shows a similar “COVID bubble” – growth stocks’ relative strength to value is well above historical levels, but now reverting, as the vaccination program proceeds (**Figure 5**).

We have shown in the above charts of the relationship between China’s PPI cycle, commodity strength and the US 10-year yield. In the near term, China’s PPI is likely to rise further, concurrent with the rise in the US 10-year yield. As such, the US bond volatility will likely increase in the coming months.


In **Figure 5**, we show that bond market volatility is inversely correlated with the relative strength of growth stocks. Growth stocks are essentially long-duration assets, as evidenced by their high valuation multiples. Intuitively, in a steady environment, it is much easier to extrapolate growth into a distant horizon. So, as bond market volatility rises, it will pressure the valuation of long-duration assets, such as growth stocks.



**Figure 5: Rising bond market vol will pressure growth valuation, dragging down its relative strength further**


Source: Bloomberg, BOCOM Int'l estimates

We can further show that China's cyclical sectors have outperformed, as the recovery unfolds (**Figure 6**). Indeed, the strength in the cyclical sectors may have surprised most. When we first forecasted the comeback of cyclicals in our 2021 outlook ("**Outlook 2021: Value Strikes Back**", 2020-11-20), most found it incredulous. But now that the cyclical strength has gradually become consensus, and cyclicals' strong performance seems to have reflected the economic recovery, what other market opportunities are there in the next phase of the recovery?

**Figure 6: Cyclical sectors have outperformed, as the recovery unfolds**



Source: Bloomberg, BOCOM Int'l estimates

## China Market Strategy

We can further dissect value and growth into cyclical value/growth and non-cyclical value/growth. We can show that both cyclical growth and non-cyclical growth have outperformed, although their outperformance is unwinding. Meanwhile, cyclical value and non-cyclical value are reverting some of their underperformance (**Figure 7**). These observations are consistent with **Figure 5** and **6** in previous sections.

That is, even though value is striking back, its strength is still crescent. But the strength in growth stocks is ebbing. As such, the value stocks, be they cyclical or non-cyclical, will remain the best place to be in the next phase of economic recovery.

**Figure 7: Cyclical and non-cyclical value is strengthening, while cyclical and non-cyclical growth is waning**




Source: Bloomberg, BOCOM Int'l estimates

## Geopolitical Risks Likely to Hamper the Market


The exchange of harsh rhetoric during the recent high-level dialogue in Alaska highlighted the tension between the two great powers. Geopolitical risks abound, and RMB has been a good proxy of such risks historically. We can show that each time the depreciation of RMB coincides with political or economic risks, such as during the 2008 financial crisis, and during the 2018 China-US trade war (**Figure 8**).

Further, the weakening of the RMB tended to lead by the yield gap, which is now rapidly narrowing. The RMB depreciation is likely concurrent with a weak Shanghai Composite. Of course, currency, bond yield and the stock market are merely a reflection of the underlying economy that tends to underperform amid economic or geopolitical risks. But the ongoing recovery is likely to offset these headwinds to a certain extent.

**Figure 8: Geopolitical risks abound, and yield gap is narrowing, presaging a weakening currency**

Source: Bloomberg, BOCOM Int'l estimates

Overall, the market return relative to economic growth is high compared with historical trends. The YoY change in the ratio of market value (MV) to GDP tends to top out at around 7%. Above that level, it is either during the bubble years of 2007 and 2015, or during the 2009 recovery phase. Even when the YoY change in MV/GDP ratio rose above 7% after early August 2009, the Shanghai Composite stopped making new highs and lingered sideways for months before falling again in early 2010, when the PBoC started to tighten. As such, we continue to believe that the market's opportunity lies with value rotation, or a change in internal market structure, rather than the absolute index level.

**Figure 9: Market return high by historical standard**

Source: Bloomberg, BOCOM Int'l estimates



## Recent Reports

20150209	Option D-Day and the Story of Red Temple	20171114	Decoding disinflation: principal contradiction, social progress and market fragility
20150302	Interest Rate Cut and the New Extremes	20171204	Outlook 2018: View from the Peak
20150320	Price-to-Whatever Ratio: A Bubble Scenario	20180131	The Year of the Dog: Lessons from 2017
20150330	One-Belt-One-Road and A New World Order	20180207	Markets in Crisis
20150413	Hang Seng = 32,000; Don't fight China's Big Mama	20180323	An Unconventional War
20150416	A50/500 Index Futures: Pricking the ChiNext Bubble	20180326	1987
20150420	CSRC, PBOC and the Greed of Man	20180409	War on War
20150506	Taming the People's Daily Bull	20180423	Great Powers Collide
20150511	Rate Cut As Expected	20180521	2H18 Outlook: Rough Sailing
20150528	"5-30" Once More	20180614	A Definitive Guide to Speculating in China
20150616	The Great China Bubble: Lessons from 800 Years of History	20180703	Where is the Bottom?
20150624	Remembering "2013-6-25"	20180723	Rebound vs Bottom
20150629	The PBOC cuts. Now what?	20180813	A Lifeline for the Market
20150702	The CSRC steps in. Now what?	20180903	The Colliding Cycles of the US and China
20150706	Shock and Awe	20181029	Market Rescue: Will It Work?
20151026	The PBoC cuts. It's time for a resolution	20181119	Outlook 2019: Turning a Corner
20151109	Re-opening IPO: Devils in Details	20190201	Turning a Corner: Teachings from "the Dog"
20151116	A winter of violence	20190301	A Margin Bull. What Next?
20151130	Three Market Extremes	20190311	Who's Buying? Who's Next?
20151209	Outlook 2016: The Chinese Curse	20190322	Market Inflection Point is Confirmed
20151217	The Fed Hikes: Moment of Truth	20190415	Cyclical Inflection Point is Confirmed
20160105	China's Circuit Breaker: The First Cut is the Deepest	20190514	War and Peace
20160108	Circuit Breaker Suspended. Now What?	20190530	Outlook 2H19: What Price for the Trade War
20160115	An Oversold Reprieve	20190628	The Art of Voting
20160121	Weak Hands	20190920	A Definitive Guide to Forecasting China Market
20160125	Stabilizing an Unstable Market	20191111	Outlook 2020: Going the Distance
20160203	One Last Ditch to Salvage the Property Bubble	20191230	The Next Decade: the Ebbing Waves
20160217	Historic Lending! But Three Important Limits	20200207	Impact of nCoV outbreak on market and economy
20160301	No Growth, No Gain	20200210	Epidemic at turning point; economic cost of quarantine
20160307	Two-Sessions in a Cyclical Spring	20200224	Spell of liquidity easing
20160321	Unprecedented Divergences	20200228	The Curse of Plague
20160418	Sweet and Sour Hog Cycle	20200302	Unconventional Risk Hedging Strategies at Cycle's End
20160503	Ant Financial: A Unicorn's Defining Moment	20200309	Stock Market Populism
20160606	The Market Bottom: When and Where	20200310	Is China a "Safe Haven"?
20160613	The Great China Bubble: Anniversary Lessons and Outlook	20200316	Fighting COVID-19, Chinese Style
20160627	Post Brexit: How to Trade China.	20200323	Hopes and Hypes
20160817	Shenzhen-Hong Kong Connect: A New Era for China's Capital Market and Capital Account	20200324	The Fed Goes All In
20160822	Consolidation	20200330	Guesstimating Unemployment in China
20160912	The Most Crowded Trade	20200406	The Cycle Has Turned
20161114	A Price Revolution – On Global Asset Allocation	20200420	China Market Strategy - Strong Man of Asia: Markets at a Historic Pivot
20161206	Outlook 2017: High-Wire Act	20200428	ChiNext registration system a new milestone in market reform
20170307	The Reflation Trade Is Over; Get Set for Defensive Rotation.	20200706	Is the Bull Back?
20170307	The Reflation Trade Is Over; Get Set for Defensive	20200713	Running with the Bull
20170324	A Definitive Guide to China's Economic Cycle.	20200720	3500
20170413	Price Inefficiency	20200727	Policy Signs
20170524	Re-pricing Risks under New Regulations	20200803	Dual Circulation in a Changing World
20170609	2H17 Outlook: An Idiot's Guide to China's Nifty-Fifty Run	20200810	China-US Rivalry: What It Means for Stocks
20170621	China's MSCI Inclusion: Thoughts after a Milestone	20200817	The Puzzle of Economizing Food
20170714	Market Trilemma	20200824	The Historic ChiNext Reform: What It Means and How to Trade
20170828	A Definitive Guide to China's Economic Cycle Part II – New High	20201120	Outlook 2021: Value Strikes Back
20170829	Cycle Sentiment		

## BOCOM International

10/F, Man Yee Building, 68 Des Voeux Road Central, Central, Hong Kong

Main: (852) 3766 1899 Fax: (852) 2107 4662

### Rating System

#### Analyst Stock Rating:

**Buy:** The stock's total return is expected to **exceed** that of the corresponding industry over the next 12 months.

**Neutral:** The stock's total return is expected to be **in line with** that of the corresponding industry over the next 12 months.

**Sell:** The stock's total return is expected to be **below** that of the corresponding industry over the next 12 months.

**Not-Rated:** The analyst **does not have conviction** regarding the outlook of the stock's total return relative to that of the corresponding industry over the next 12 months.

#### Analyst Industry Views:

**Outperform:** The analyst expects the industry coverage universe to be **attractive** relative to the relevant broad market benchmark over the next 12 months.

**Market perform:** The analyst expects the industry coverage universe to be **in line with** the relevant broad market benchmark over the next 12 months.

**Underperform:** The analyst expects the industry coverage universe to be **unattractive** relative to the relevant broad market benchmark over the next 12 months.

Broad market benchmark for Hong Kong is the **Hang Seng Composite Index**, for China A-shares is the **MSCI China A Index**, for US-listed Chinese companies is **S&P US Listed China 50 (USD) Index**.

27 March 2021

## China Market Strategy

### Analyst certification

The authors of this report, hereby declare that: (i) all of the views expressed in this report accurately reflect their personal views about any and all of the subject securities or issuers; and (ii) no part of any of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report; (iii) no insider information/ non-public price-sensitive information in relation to the subject securities or issuers which may influence the recommendations were being received by the authors.

The authors of this report further confirm that (i) neither they nor their respective associates (as defined in the Code of Conduct issued by the Hong Kong Securities and Futures Commission) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of the report; (ii) neither they nor their respective associates serve as an officer of any of the Hong Kong listed companies covered in this report; and (iii) neither they nor their respective associates have any financial interests in the stock(s) covered in this report except for one coverage analyst who is holding shares of Shimao Property Holdings Limited.

### Disclosure of relevant business relationships

BOCOM International Securities Limited, and/or its associated companies, has investment banking relationship with Bank of Communications, Guolian Securities Co. Ltd., Luzhou Xinglu Water (Group) Co., Ltd., BOCOM International Holdings Company Limited, Sichuan Energy Investment Development Co., Ltd, Light Year Holdings Limited, Analogue Holdings Limited, Zhejiang New Century Hotel Management Co., Ltd, Tai Hing Group Holdings Limited, Shanghai Kindly Medical Instruments Co, Ltd, China Bright Culture Group, Jinchuan Group International Resources Co. Ltd, JiaXing Gas Group Co., Ltd, Honliv Healthcare Management Group Company Limited, Joy Spreader Interactive Technology. Ltd, Fu Shek Financial Holdings Limited, Xingye Wulian Service Group Co Ltd, Jiu Zun Digital Interactive Entertainment Group Holdings Limited, Cirtex Holdings Limited, Kidztech Holdings Limited, Akeso, Inc., JD.com, Inc, Qingdao Holdings International Limited, Immunotech Biopharm Ltd, Ganglong China Property Group Limited, Sino-Entertainment Technology Holdings Limited, Dashan Education Holdings Limited, Adtiger Corporations Limited, China Bohai Bank Co., Ltd., Fulu Holdings Limited, China Nature Energy Technology Holdings Limited, RemeGen Co., Ltd., Shinsun Holdings (Group) Co., Ltd., JD Health International Inc., Leading Group Holdings Limited, Datang Group Holdings Limited, Jiayuan Services Holdings Limited, Netjoy Holdings Limited, China Gas Industry Investment Holdings Co. Ltd., Raily Aesthetic Medicine International Holdings Limited, Legion Consortium Limited, Cheshi Holdings Limited, Deyun Holdings Ltd., Mediwelcome Healthcare Service and Technology Inc., Modern Chinese Medicine Group Co., Ltd., Roiserv Lifestyle Services Co., Ltd., Strawbear Entertainment Group, 500.com Limited, Oriental University City Holdings (H.K.) Limited, JOINN Laboratories (China) Co., Ltd., Morimatsu International Holdings Company Limited, and Megain Holding (Cayman) Co., Ltd within the preceding 12 months.

BOCOM International Global Investment Limited currently holds more than 1% of the equity securities of Orient Securities Company Limited.

BOCOM International Global Investment Limited currently holds more than 1% of the equity securities of Everbright Securities Company Limited.

BOCOM International Global Investment Limited currently holds more than 1% of the equity securities of Guolian Securities Co., Ltd.

### Disclaimer

By accepting this report (which includes any attachment hereto), the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of law.

This report is strictly confidential and is for private circulation only to clients of BOCOM International Securities Ltd. This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of BOCOM International Securities Ltd.

BOCOM International Securities Ltd, its affiliates and related companies, their directors, associates, connected parties and/or employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be interested in, any such securities. Further, BOCOM International Securities Ltd, its affiliates and its related companies may do and seek to do business with the company(ies) covered in this report and may from time to time act as market maker or have assumed an underwriting commitment in securities of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking, advisory, underwriting, financing or other services for or relating to such company(ies) as well as solicit such investment, advisory, financing or other services from any entity mentioned in this report. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

The information contained in this report is prepared from data and sources believed to be correct and reliable at the time of issue of this report. This report does not purport to contain all the information that a prospective investor may require and may be subject to late delivery, interruption and interception. BOCOM International Securities Ltd does not make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report and accordingly, neither BOCOM International Securities Ltd nor any of its affiliates nor its related persons shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst BOCOM International Securities Ltd's clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments thereof.

The views, recommendations, advice and opinions in this report may not necessarily reflect those of BOCOM International Securities Ltd or any of its affiliates, and are subject to change without notice. BOCOM International Securities Ltd has no obligation to update its opinion or the information in this report.

Investors are advised to make their own independent evaluation of the information contained in this research report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to any law, regulation, rule or other registration or licensing requirement.

**BOCOM International Securities Ltd is a subsidiary of Bank of Communications Co Ltd.**